About: Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution”

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution” Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution”
Creator	Lebwohl, Mark Murrell, Dedee Rivera-Oyola, Ryan Waldman, Eric
source	Elsevier; Medline; PMC
abstract	covid:c02992571a8d15b82e8beeb4332b5caead05b346#abstract
has issue date	2020-04-10(xsd:dateTime)
bibo:doi	10.1016/j.jaad.2020.03.103
bibo:pmid	32283232
has license	els-covid
sha1sum (hex)	c02992571a8d15b82e8beeb4332b5caead05b346
schema:url	https://doi.org/10.1016/j.jaad.2020.03.103
resource representing a document's title	Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution”
has PubMed Central identifier	PMC7151396
has PubMed identifier	32283232
schema:publication	J Am Acad Dermatol
resource representing a document's body	covid:c02992571a8d15b82e8beeb4332b5caead05b346#body_text
is schema:about of	named entity 'long-term' named entity 'cyclosporine' named entity 'COVID-19 pandemic' named entity 'inflammation' named entity 'biologic therapies' named entity 'infection' named entity 'skin disease' named entity 'immunomodulators' named entity 'COVID' named entity 'screening tests' named entity 'biologics' named entity 'mycobacterial' named entity 'atopic dermatitis' named entity 'COVID' named entity 'syphilis' named entity 'p40' named entity 'asthma' named entity 'methotrexate' named entity 'host defenses' named entity 'data reporting' named entity 'salmonella infections' named entity 'COVID-19 infection' named entity 'biologic agents' named entity 'psoriasis' named entity 'viral infections' named entity 'syphilis' named entity 'chronic mucocutaneous candidiasis' named entity 'immunosuppressants' named entity 'biologics' named entity 'interleukin 17' named entity 'Strongyloides' named entity 'influenza' named entity 'COVID-19' named entity 'pneumonia' named entity 'psoriatic arthritis' named entity 'biologics' named entity 'clinical trial' named entity 'All India Institute of Medical Sciences' named entity 'biologic agents' named entity 'viral infections' named entity 'tumor necrosis factor' named entity 'immunosuppressive drugs' named entity 'COVID-19' named entity 'dupilumab' named entity 'leprosy' named entity 'psoriasis' named entity 'vector' named entity 'viral infection' named entity 'National Psoriasis Foundation' named entity 'infection' named entity 'biologic agents' named entity 'American Academy of Dermatology'
is part of of	covid:c02992571a8d15b82e8beeb4332b5caead05b346#body_text covid:c02992571a8d15b82e8beeb4332b5caead05b346#abstract Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution”

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software